clinical trial · NCT06601192
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
Enanta Pharmaceuticals, Inc·phase1·completed·n = 72
RSV InfectionQTc Intervalzelicapavir (therapeutic dose)zelicapavir (supratherapeutic dose)Placebomoxifloxacin
brief summary
The purpose of the study is to assess the effect of a therapeutic and supratherapeutic dose of zelicapavir on the corrected cardiac QT interval relative to a placebo and positive control in healthy participants.
started
Jul 15, 2024
primary completion
Feb 2, 2025
completion
Feb 25, 2025
last updated
Jul 28, 2025
official title
Phase 1, Randomized, Double-Blind Four-Period Crossover, Thorough QT/QTc Study to Evaluate the Effects of EDP-938 on Cardiac Repolarization in Healthy Adults
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol